CN100357737C - 特异结合反应测定方法、测定装置以及其中所用试剂盒 - Google Patents
特异结合反应测定方法、测定装置以及其中所用试剂盒 Download PDFInfo
- Publication number
- CN100357737C CN100357737C CNB2003101142779A CN200310114277A CN100357737C CN 100357737 C CN100357737 C CN 100357737C CN B2003101142779 A CNB2003101142779 A CN B2003101142779A CN 200310114277 A CN200310114277 A CN 200310114277A CN 100357737 C CN100357737 C CN 100357737C
- Authority
- CN
- China
- Prior art keywords
- determined material
- specific
- reaction system
- antibody
- magnetic particle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000006243 chemical reaction Methods 0.000 title claims abstract description 317
- 238000000034 method Methods 0.000 title abstract description 34
- 239000006249 magnetic particle Substances 0.000 claims abstract description 181
- 239000000126 substance Substances 0.000 claims abstract description 170
- 230000003287 optical effect Effects 0.000 claims abstract description 60
- 239000000463 material Substances 0.000 claims description 284
- 150000001875 compounds Chemical class 0.000 claims description 91
- 239000000427 antigen Substances 0.000 claims description 76
- 102000036639 antigens Human genes 0.000 claims description 76
- 108091007433 antigens Proteins 0.000 claims description 76
- 108020004414 DNA Proteins 0.000 claims description 61
- 238000009739 binding Methods 0.000 claims description 44
- 238000003556 assay Methods 0.000 claims description 43
- 230000009870 specific binding Effects 0.000 claims description 40
- 102000053602 DNA Human genes 0.000 claims description 38
- 108020004682 Single-Stranded DNA Proteins 0.000 claims description 38
- 239000002131 composite material Substances 0.000 claims description 31
- 238000006062 fragmentation reaction Methods 0.000 claims description 25
- 229920000151 polyglycol Polymers 0.000 claims description 19
- 239000010695 polyglycol Substances 0.000 claims description 19
- 102000001554 Hemoglobins Human genes 0.000 claims description 15
- 108010054147 Hemoglobins Proteins 0.000 claims description 15
- 238000013467 fragmentation Methods 0.000 claims description 13
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 9
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 9
- 230000004520 agglutination Effects 0.000 abstract description 11
- 238000005859 coupling reaction Methods 0.000 abstract 4
- 230000008878 coupling Effects 0.000 abstract 3
- 238000010168 coupling process Methods 0.000 abstract 3
- 230000036046 immunoreaction Effects 0.000 description 62
- 238000000691 measurement method Methods 0.000 description 62
- 238000013016 damping Methods 0.000 description 37
- 239000012530 fluid Substances 0.000 description 37
- 102000004169 proteins and genes Human genes 0.000 description 34
- 108090000623 proteins and genes Proteins 0.000 description 34
- 230000005540 biological transmission Effects 0.000 description 33
- 239000002245 particle Substances 0.000 description 20
- 230000003281 allosteric effect Effects 0.000 description 16
- 230000008859 change Effects 0.000 description 15
- 239000000243 solution Substances 0.000 description 14
- 102000009027 Albumins Human genes 0.000 description 12
- 108010088751 Albumins Proteins 0.000 description 12
- 230000000295 complement effect Effects 0.000 description 12
- 239000004094 surface-active agent Substances 0.000 description 12
- SHAHPWSYJFYMRX-GDLCADMTSA-N (2S)-2-(4-{[(1R,2S)-2-hydroxycyclopentyl]methyl}phenyl)propanoic acid Chemical compound C1=CC([C@@H](C(O)=O)C)=CC=C1C[C@@H]1[C@@H](O)CCC1 SHAHPWSYJFYMRX-GDLCADMTSA-N 0.000 description 11
- 230000008569 process Effects 0.000 description 11
- DVLFYONBTKHTER-UHFFFAOYSA-N 3-(N-morpholino)propanesulfonic acid Chemical compound OS(=O)(=O)CCCN1CCOCC1 DVLFYONBTKHTER-UHFFFAOYSA-N 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- 239000007993 MOPS buffer Substances 0.000 description 9
- 238000010586 diagram Methods 0.000 description 9
- 238000004848 nephelometry Methods 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 239000002253 acid Substances 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 239000004816 latex Substances 0.000 description 8
- 229920000126 latex Polymers 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- ARIWANIATODDMH-UHFFFAOYSA-N rac-1-monolauroylglycerol Chemical compound CCCCCCCCCCCC(=O)OCC(O)CO ARIWANIATODDMH-UHFFFAOYSA-N 0.000 description 8
- 238000004879 turbidimetry Methods 0.000 description 8
- 101710153593 Albumin A Proteins 0.000 description 7
- 230000000621 autoagglutination Effects 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 210000003734 kidney Anatomy 0.000 description 7
- 210000002700 urine Anatomy 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 229940125898 compound 5 Drugs 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 6
- RWWYLEGWBNMMLJ-YSOARWBDSA-N remdesivir Chemical compound NC1=NC=NN2C1=CC=C2[C@]1([C@@H]([C@@H]([C@H](O1)CO[P@](=O)(OC1=CC=CC=C1)N[C@H](C(=O)OCC(CC)CC)C)O)O)C#N RWWYLEGWBNMMLJ-YSOARWBDSA-N 0.000 description 6
- 210000001124 body fluid Anatomy 0.000 description 5
- 239000010839 body fluid Substances 0.000 description 5
- 238000000502 dialysis Methods 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 4
- OVDGUTHABMXVMI-UHFFFAOYSA-N 3-nitro-4-(propylamino)benzoic acid Chemical compound CCCNC1=CC=C(C(O)=O)C=C1[N+]([O-])=O OVDGUTHABMXVMI-UHFFFAOYSA-N 0.000 description 4
- 241000283707 Capra Species 0.000 description 4
- 208000035473 Communicable disease Diseases 0.000 description 4
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- RCEAADKTGXTDOA-UHFFFAOYSA-N OS(O)(=O)=O.CCCCCCCCCCCC[Na] Chemical compound OS(O)(=O)=O.CCCCCCCCCCCC[Na] RCEAADKTGXTDOA-UHFFFAOYSA-N 0.000 description 4
- 229920001213 Polysorbate 20 Polymers 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 229930182478 glucoside Natural products 0.000 description 4
- 239000003292 glue Substances 0.000 description 4
- 229940068939 glyceryl monolaurate Drugs 0.000 description 4
- 239000003163 gonadal steroid hormone Substances 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- -1 octyl group glucosides Chemical class 0.000 description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 229910052938 sodium sulfate Inorganic materials 0.000 description 4
- 235000011152 sodium sulphate Nutrition 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 208000000143 urethritis Diseases 0.000 description 4
- 229910000859 α-Fe Inorganic materials 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 239000012149 elution buffer Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 206010061216 Infarction Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 206010037596 Pyelonephritis Diseases 0.000 description 2
- 238000011481 absorbance measurement Methods 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000011095 buffer preparation Methods 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 230000003139 buffering effect Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 201000003146 cystitis Diseases 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 239000003219 hemolytic agent Substances 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000007574 infarction Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 201000007094 prostatitis Diseases 0.000 description 2
- 235000019624 protein content Nutrition 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 208000015924 Lithiasis Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- HGAZMNJKRQFZKS-UHFFFAOYSA-N chloroethene;ethenyl acetate Chemical compound ClC=C.CC(=O)OC=C HGAZMNJKRQFZKS-UHFFFAOYSA-N 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 235000013905 glycine and its sodium salt Nutrition 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010439 graphite Substances 0.000 description 1
- 229910002804 graphite Inorganic materials 0.000 description 1
- 230000003760 hair shine Effects 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 108010014561 ovomucoid inhibitors Proteins 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 239000010048 yiguan Substances 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/47—Scattering, i.e. diffuse reflection
- G01N21/49—Scattering, i.e. diffuse reflection within a body or fluid
- G01N21/51—Scattering, i.e. diffuse reflection within a body or fluid inside a container, e.g. in an ampoule
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
- G01N33/54326—Magnetic particles
- G01N33/54333—Modification of conditions of immunological binding reaction, e.g. use of more than one type of particle, use of chemical agents to improve binding, choice of incubation time or application of magnetic field during binding reaction
Abstract
Description
Claims (15)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002328056 | 2002-11-12 | ||
JP2002328056 | 2002-11-12 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1499203A CN1499203A (zh) | 2004-05-26 |
CN100357737C true CN100357737C (zh) | 2007-12-26 |
Family
ID=32171356
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2003101142779A Expired - Fee Related CN100357737C (zh) | 2002-11-12 | 2003-11-12 | 特异结合反应测定方法、测定装置以及其中所用试剂盒 |
Country Status (4)
Country | Link |
---|---|
US (2) | US7105359B2 (zh) |
EP (1) | EP1420251B1 (zh) |
KR (1) | KR20040044336A (zh) |
CN (1) | CN100357737C (zh) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101467044A (zh) * | 2006-07-13 | 2009-06-24 | 奥林巴斯株式会社 | 微粒的样品检测活性的确认方法 |
GB0616508D0 (en) * | 2006-08-18 | 2006-09-27 | Iti Scotland Ltd | Analyte manipulation and detection |
EP1980853A1 (en) * | 2007-04-11 | 2008-10-15 | Alfresa Pharma Corporation | Method of preventing precipitation of a reactive substance-bound microparticle, and reagent containing the micro particle |
US20080261328A1 (en) * | 2007-04-19 | 2008-10-23 | Alfresa Pharma Corporation | Method of preventing precipitation of a reactive substance-bound microparticle, and reagent containing the micro particle |
JP2010151777A (ja) * | 2008-11-19 | 2010-07-08 | Sony Corp | 微小粒子解析装置、微小粒子解析用マイクロチップ及び微小粒子解析方法 |
KR20120107497A (ko) | 2009-12-17 | 2012-10-02 | 아박시스, 인크. | 샘플 내 분석물을 검출하기 위한 신규 분석 및 그것과 관련된 키트 및 조성물 |
CN110251766A (zh) | 2012-02-20 | 2019-09-20 | 泰尔茂株式会社 | 医疗用具包装体 |
WO2015122749A1 (ko) * | 2014-02-17 | 2015-08-20 | 서울바이오시스 주식회사 | 체액 분석 장치 및 이를 이용하는 체액 분석 방법 |
KR102018895B1 (ko) * | 2016-11-01 | 2019-09-06 | 주식회사 더웨이브톡 | 혼돈파 센서를 이용한 바이러스 검출 장치 및 이를 이용한 바이러스 검출 방법 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5238810A (en) * | 1986-09-22 | 1993-08-24 | Nippon Telegraph And Telephone Corporation | Laser magnetic immunoassay method and apparatus thereof |
CN1208621A (zh) * | 1997-08-15 | 1999-02-24 | 刘茂林 | “胎宝”胶囊中药及其制备工艺 |
US5993740A (en) * | 1995-01-20 | 1999-11-30 | Hitachi, Ltd. | Immunoassay method and analyzer using magnetic particles |
WO2001014591A1 (en) * | 1999-08-21 | 2001-03-01 | Fox John S | High sensitivity biomolecule detection with magnetic particles |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1575805A (en) * | 1976-03-12 | 1980-10-01 | Technicon Instr | Automatic diagnostic apparatus |
US4115534A (en) * | 1976-08-19 | 1978-09-19 | Minnesota Mining And Manufacturing Company | In vitro diagnostic test |
US5071774A (en) * | 1983-04-05 | 1991-12-10 | Syntex (U.S.A.) Inc. | Multiparameter particle analysis |
US5076950A (en) * | 1985-12-20 | 1991-12-31 | Syntex (U.S.A.) Inc. | Magnetic composition for particle separation |
JPH0737989B2 (ja) | 1986-07-04 | 1995-04-26 | 東ソー株式会社 | 免疫反応の測定方法および装置 |
US5145784A (en) * | 1988-05-04 | 1992-09-08 | Cambridge Biotech Corporation | Double capture assay method employing a capillary flow device |
WO1992008133A1 (en) * | 1990-10-29 | 1992-05-14 | Dekalb Plant Genetics | Isolation of biological materials using magnetic particles |
DE69125797T2 (de) | 1990-11-28 | 1997-10-09 | Hitachi Ltd | Analyseverfahren und -vorrichtung für flüssige Proben |
US5646001A (en) * | 1991-03-25 | 1997-07-08 | Immunivest Corporation | Affinity-binding separation and release of one or more selected subset of biological entities from a mixed population thereof |
US5286452A (en) * | 1991-05-20 | 1994-02-15 | Sienna Biotech, Inc. | Simultaneous multiple assays |
TW239881B (zh) * | 1992-12-22 | 1995-02-01 | Sienna Biotech Inc | |
JP2842758B2 (ja) * | 1993-05-10 | 1999-01-06 | 株式会社日立製作所 | 自動分析装置 |
US6586193B2 (en) * | 1996-04-25 | 2003-07-01 | Genicon Sciences Corporation | Analyte assay using particulate labels |
DK0925494T3 (da) * | 1996-09-04 | 2002-07-01 | Scandinavian Micro Biodevices | Mikrostrømningssystem til partikelseparation og analyse |
DE69812329T2 (de) * | 1997-11-18 | 2004-02-12 | Bio-Rad Laboratories, Inc., Hercules | Multiplex-zufluss-immunotest mit magnetischen teilchen als festphase |
US6046585A (en) | 1997-11-21 | 2000-04-04 | Quantum Design, Inc. | Method and apparatus for making quantitative measurements of localized accumulations of target particles having magnetic particles bound thereto |
CA2312102C (en) * | 1997-12-24 | 2007-09-04 | Cepheid | Integrated fluid manipulation cartridge |
US6290839B1 (en) * | 1998-06-23 | 2001-09-18 | Clinical Micro Sensors, Inc. | Systems for electrophoretic transport and detection of analytes |
US6087182A (en) * | 1998-08-27 | 2000-07-11 | Abbott Laboratories | Reagentless analysis of biological samples |
AU3372800A (en) * | 1999-02-23 | 2000-09-14 | Caliper Technologies Corporation | Manipulation of microparticles in microfluidic systems |
JP2000346843A (ja) | 1999-06-02 | 2000-12-15 | Tdk Corp | 免疫学的多項目測定方法 |
EP1072887B1 (en) * | 1999-07-30 | 2005-11-16 | Mitsubishi Chemical Corporation | Immunoassay |
US6254830B1 (en) * | 1999-11-05 | 2001-07-03 | The Board Of Governors For Higher Education, State Of Rhode Island And Providence Plantations | Magnetic focusing immunosensor for the detection of pathogens |
US6432290B1 (en) * | 1999-11-26 | 2002-08-13 | The Governors Of The University Of Alberta | Apparatus and method for trapping bead based reagents within microfluidic analysis systems |
DE60116689T2 (de) * | 2000-07-27 | 2006-08-31 | Sysmex Corp. | Vollblut-Immunoassay |
US6797481B1 (en) * | 2000-10-17 | 2004-09-28 | Dade Behring Marburg Gmbh | Simultaneous screening of multiple analytes |
US6649419B1 (en) * | 2000-11-28 | 2003-11-18 | Large Scale Proteomics Corp. | Method and apparatus for protein manipulation |
US20040219695A1 (en) * | 2002-01-19 | 2004-11-04 | Fox John Stewart | High sensitivity detection of and manipulation of biomolecules and cells with magnetic particles |
-
2003
- 2003-11-12 CN CNB2003101142779A patent/CN100357737C/zh not_active Expired - Fee Related
- 2003-11-12 KR KR1020030079759A patent/KR20040044336A/ko not_active Application Discontinuation
- 2003-11-12 EP EP03026068A patent/EP1420251B1/en not_active Expired - Lifetime
- 2003-11-12 US US10/704,802 patent/US7105359B2/en not_active Expired - Lifetime
-
2006
- 2006-08-21 US US11/507,011 patent/US7553676B2/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5238810A (en) * | 1986-09-22 | 1993-08-24 | Nippon Telegraph And Telephone Corporation | Laser magnetic immunoassay method and apparatus thereof |
US5993740A (en) * | 1995-01-20 | 1999-11-30 | Hitachi, Ltd. | Immunoassay method and analyzer using magnetic particles |
CN1208621A (zh) * | 1997-08-15 | 1999-02-24 | 刘茂林 | “胎宝”胶囊中药及其制备工艺 |
WO2001014591A1 (en) * | 1999-08-21 | 2001-03-01 | Fox John S | High sensitivity biomolecule detection with magnetic particles |
Also Published As
Publication number | Publication date |
---|---|
US20040096909A1 (en) | 2004-05-20 |
KR20040044336A (ko) | 2004-05-28 |
US7553676B2 (en) | 2009-06-30 |
EP1420251A1 (en) | 2004-05-19 |
US7105359B2 (en) | 2006-09-12 |
CN1499203A (zh) | 2004-05-26 |
EP1420251B1 (en) | 2013-01-09 |
US20060281195A1 (en) | 2006-12-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU620343B2 (en) | Metal sol capture immunoassay procedure, kit for use therewith and captured metal containing composite | |
US4279617A (en) | Iummunoassay involving agglutination | |
CA1308349C (en) | Agglutination immunoassay and kit for determination of a multivalent immune species using a buffered salt wash solution | |
CA2177288C (en) | Rapid immunoassay for detection of antibodies or antigens incorporating simultaneous sample extraction and immunogenic reaction | |
AU693236B2 (en) | Test device and method for colored particle immunoassay | |
CN105324489A (zh) | 多分析物试验 | |
EP1957978B1 (fr) | Procede magnetique d'immunodiagnostic pour la mise en evidence de complexe anticorps/antigene, en particulier de groupe sanguin | |
CN101243321A (zh) | 用于检测抗-类脂抗体的方法、免疫测定法和装置 | |
CN100357737C (zh) | 特异结合反应测定方法、测定装置以及其中所用试剂盒 | |
CN101711363A (zh) | 血液样品的多重分析 | |
CA2200683A1 (en) | Method for detecting antibodies | |
CA2565114A1 (fr) | Utilisation de ferrofluides pour le phenotypage sanguin et applications derivees | |
AU652637B2 (en) | Assay of specific antibody | |
US4210622A (en) | Kit for assay of immune complexes | |
US5132085A (en) | Test device with novel control symbolism | |
US4141965A (en) | Assay of immune complexes | |
CN104823051A (zh) | 多分析物试验 | |
Scott et al. | Comparison of enzyme immunoassay and latex agglutination methods for detection of Cryptococcus neoformans antigen | |
KR20210003721A (ko) | 비드를 포함하는 시험관내 진단 장치 및 그 용도 | |
CN101356438A (zh) | 评估人半胱氨酸蛋白酶抑制剂c的浊度测定法免疫测定 | |
JP4451637B2 (ja) | 特異結合反応測定方法、それに用いる試薬キット | |
AU625344B2 (en) | Chlamydia half-sandwich immunoassay | |
JPH0643164A (ja) | 歯周疾患に随伴する微生物類の分別ならびにそれに有用な製品およびキット | |
Wilson et al. | Passive allergisation in vitro of human basophils with serum containing IgE reaginic antibodies to castor allergen, demonstrated by rosette-formation | |
JPH0510954A (ja) | バクテロイデス・インターメデイウス、バクテロイデス・ギンギバリスまたはアクチノバシラス・アクチノマイセテムコミタンスの検出用製品、試験キツトおよびサンドイツチアツセイ |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: PANASONIC HEALTHCARE + MEDICAL EQUIPMENT CO., LTD. Free format text: FORMER OWNER: MATSUSHITA ELECTRIC INDUSTRIAL CO, LTD. Effective date: 20140516 |
|
C41 | Transfer of patent application or patent right or utility model | ||
C56 | Change in the name or address of the patentee | ||
CP03 | Change of name, title or address |
Address after: Osaka Japan Patentee after: Matsushita Electric Industrial Co.,Ltd. Address before: Osaka Japan Patentee before: Matsushita Electric Industrial Co.,Ltd. |
|
TR01 | Transfer of patent right |
Effective date of registration: 20140516 Address after: Japan Ehime Prefecture Patentee after: PANASONIC Corp. Address before: Osaka Japan Patentee before: Matsushita Electric Industrial Co.,Ltd. |
|
ASS | Succession or assignment of patent right |
Owner name: PANASONIC HEALTHCARE HOLDINGS CO., LTD. Free format text: FORMER OWNER: PANASONIC HEALTHCARE + MEDICAL EQUIPMENT CO., LTD. Effective date: 20150409 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20150409 Address after: Tokyo, Japan Patentee after: PANASONIC HEALTHCARE HOLDINGS CO.,LTD. Address before: Japan Ehime Prefecture Patentee before: PANASONIC Corp. |
|
CP01 | Change in the name or title of a patent holder |
Address after: Tokyo, Japan Patentee after: Puhexi Holdings Address before: Tokyo, Japan Patentee before: PANASONIC HEALTHCARE HOLDINGS CO.,LTD. |
|
CP01 | Change in the name or title of a patent holder | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20071226 |